RT Journal Article
SR Electronic
T1 Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.23.22270017
DO 10.1101/2022.03.23.22270017
A1 Osmanodja, Bilgin
A1 Ronicke, Simon
A1 Budde, Klemens
A1 Jens, Annika
A1 Hammett, Charlotte
A1 Koch, Nadine
A1 Seelow, Evelyn
A1 Waiser, Johannes
A1 Zukunft, Bianca
A1 Bachmann, Friederike
A1 Choi, Mira
A1 Weber, Ulrike
A1 Eberspächer, Bettina
A1 Hofmann, Jörg
A1 Grunow, Fritz
A1 Mikhailov, Michael
A1 Liefeldt, Lutz
A1 Eckardt, Kai-Uwe
A1 Halleck, Fabian
A1 Schrezenmeier, Eva
YR 2022
UL http://medrxiv.org/content/early/2022/03/27/2022.03.23.22270017.abstract
AB Mortality from COVID-19 among kidney transplant recipients (KTR) is high, and their response to three vaccinations against SARS-CoV-2 is strongly impaired.We retrospectively analyzed serological response of up to five doses of SARS-CoV-2 vaccine in KTR from December 27, 2020, until December 31, 2021. Particularly, the influence of different dose adjustment regimens for mycophenolic acid (MPA) on serological response to fourth vaccination was analyzed.In total, 4.277 vaccinations against SARS-CoV-2 in 1.478 patients were analyzed. Serological response was 19.5% after 1.203 basic immunizations, and increased to 29.4%, 55.6%, and 57.5% in response to 603 third, 250 fourth and 40 fifth vaccinations, resulting in a cumulative response rate of 88.7%.In patients with calcineurin inhibitor and MPA maintenance immunosuppression, pausing MPA and adding 5 mg prednisolone equivalent before the fourth vaccination increased serological response rate to 75% in comparison to no dose adjustment (52%) or dose reduction (46%). Belatacept-treated patients had a response rate of 8.7% (4/46) after three vaccinations and 12.5% (3/25) after four vaccinations.Except for belatacept-treated patients, repeated SARS-CoV-2 vaccination of up to five times effectively induces serological response in kidney transplant recipients. It can be enhanced by pausing MPA at the time of vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of Charité - Universitätsmedizin Berlin gave ethical approval for this work (EA1/030/22)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. CNIcalcineurin inhibitorCOVID-19coronavirus disease 2019eGFRestimated glomerular filtration rateELISAenzyme-linked immunosorbent assaysKTRkidney transplant recipientsMPAmycophenolic acidNnucleocapsid proteinRBDreceptor binding domainSspike proteinSARS-CoV-2severe acute respiratory syndrome coronavirus 2SOTsolid organ transplantationTCMRT cell mediated rejection